

The present invention relates to: a composition containing a conjugate having a bioactive polypeptide linked to an immunoglobulin Fc fragment, wherein the composition is a sustained pharmaceutical composition containing a monomer conjugate having one molecule of bioactive polypeptide linked to one immunoglobulin Fc fragment, and optionally a multimer conjugate having two or more molecules of identical bioactive polypeptide linked to one immunoglobulin Fc fragment, wherein the molar ratio of the monomer conjugate to the multimer conjugate in the composition is 19 or greater; a bioactive polypeptide monomer-immuno-globulin Fc fragment conjugate in which a bioactive polypeptide monomer and an immunoglobulin Fc fragment are linked via a non-peptide linker, wherein the bioactive polypeptide is linked, in a monomer form, to one immunoglobulin Fc fragment via the non-peptide linker, and demonstrates a lower receptor-mediated internalization or receptor-mediated clearance, compared to a dimer conjugate having two molecules of bioactive polypeptide linked to one immunoglobulin Fc fragment via a non-peptide polymer, or a bioactive polypeptide-immunoglobulin Fc fragment inframe conjugate; and a method for preparing the sustained pharmaceutical composition.